Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer

Modern Pathology

Volumn 22, Issue 2, 2009, Pages 282-290

  Tay, Wei Lin ^a   Yip, George Wai Cheong ^a   Tan, Puay Hoon ^a,b   Matsumoto, Ken ^c   Yeo, Richard ^d   Ng, Tze Pin ^e   Kumar, Srinivasan Dinesh ^a   Tsujimoto, Masafumi ^c   Bay, Boon Huat ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^e NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Chemoradiotherapy; Immunohistochemistry; Nasopharyngeal carcinoma; Radiotherapy; Y Box binding protein 1

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PROTEIN; Y BOX BINDING PROTEIN 1;

ARTICLE; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER RISK; CANCER TISSUE; CELL MEMBRANE; CHEMOSENSITIVITY; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; NASOPHARYNX CANCER; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PARAMETER; PATHOLOGY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BLOTTING, WESTERN; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA, MESSENGER; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 59149097954     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.181     Document Type: Article

References (37)

1. Ferlay J, Bray F, Pisani P, et al. Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide (Version 1.0). IARC Cancer Base No. 5. IARC Press: Lyon, 2001.
2. Chan JKC, Pilch BZ, Kuo TT, et al. Tumours of the nasophrynx: introduction. In: Barnes L, Eveson JW, Reichart P, Sidransky D (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. IARC Press: Lyon, 2005, pp 83-84.
3. Marks JE, Phillips JL, Menck HR. The national cancer database report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 1998;83:582-588.
4. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell 2004;5:423-428.
5. Lee AW. Contribution of radiotherapy to function preservation and cancer outcome in primary treatment of nasopharyngeal carcinoma. World J Surg 2003;27:838-843.
6. Reddy SP, Raslan WF, Gooneratne S, et al. Prognostic significance of keratinization in nasopharyngeal carcinoma. Am J Otolaryngol 1995;16:103-108.
7. Ma BB, Hui EP, Chan AT. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci 2008;99:1311-1318.
8. Teo PM, Chan AT. Treatment strategy and clinical experience. Semin Cancer Biol 2002;12:497-504.
9. Guigay J. Advances in nasopharyngeal carcinoma. Curr Opin Oncol 2008;20:264-269.
10. Kohno K, Izumi H, Uchiumi T, et al. The pleiotropic functions of the Y-box binding protein YB-1. Bioessays 2003;25:691-698.
11. Matsumoto K, Wolffe AP. Gene regulation by Y-box proteins: coupling control of transcription and translation. Trends Cell Biol 1998;8:318-323.
12. Bargou RC, Jürchott K, Wagener C, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene exprsesion. Nat Med 1997;3:447-450.
13. Ohga T, Uchiumi T, Makino Y, et al. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 1998;273:5997-6000.
14. Huang JX, Tan PH, Li KB, et al. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer. Int J Oncol 2005;26:607-613.
15. Janz M, Harbeck N, Dettmar P, et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumour biologic factors HER2, uPA and PAI-1. Int J Cancer 2002;97:278-282.
16. Zhang S, Gao X, Zeng Y. Cytogenetic studies on an epithelial cell line derived from poorly differentiated nasopharyngeal carcinoma. Int J Cancer 1983;31:587-590.
17. Shibahara K, Sugio K, Osaki T, et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 2001;7:3151-3155.
18. Kamura T, Yahata H, Amada S, et al. Is nuclear expression of Y box-binding protein protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 1999;85:2450-2454.
19. Oda Y, Sakamoto A, Shinohara N, et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res 1998;4:2273-2277.
20. Jürchott K, Bergmann S, Stein U, et al. YB-1 as cell cycle regulated transcription factor facilitating cyclic A and cyclin B1 gene expression. J Biol Chem 2003;278:27988-27996.
21. Koike K, Uchiumi T, Ohga T, et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett 1997;417:390-394.
22. Zhang YF, Homer C, Edwards SJ, et al. Nuclear localization of Y-box factor YB1 requires wild-type p53. Oncogene 2003;22:2782-2794.
23. Gessner C, Woischwill C, Schumacher A, et al. Nuclear YB-1 expression as a negative prognostic marker in non-small cell lung cancer. Eur Respir J 2004;23:14-19.
24. Oda Y, Ohishi Y, Saito T, et al. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II α expression, and with poor prognosis in synovial sarcoma. J Pathol 2003;199:251-258.
25. Yasen M, Kajino K, Kano S, et al. The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. Clin Cancer Res 2005;11:7354-7361.
26. Huang X, Ushijima K, Komai K, et al. Co-expression of Y box-binding protein 1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol Oncol 2004;93:287-291.
27. Kuwano M, Oda Y, Izumi H, et al. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 2004;3:1485-1492.
28. Chaudhary PM, Roninson LB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993;85:632-639.
29. Hasegawa SL, Doetsch PW, Hamilton KK, et al. DNA binding properties of YB-1 and dbpA: binding to double-stranded, single-stranded, and abasic site containing DNAs. Nucleic Acids Res 1991;19:4915-4920.
30. Ise T, Nagatani G, Imamura T, et al. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 1999;59:342-346.
31. Okamoto T, Izumi H, Imamura T, et al. Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene 2000;19:2955-2966.
32. Chang JT, Chan SH, Lin CY, et al. Differentially expressed genes in radioresistant nasopharyngeal cancer cells: gp96 and GDF15. Mol Cancer Ther 2007;6:2271-2279.
33. Wang X, Ling MT, Guan XY, et al. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 2004;23:474-482.
34. Cheung HW, Ling MT, Tsao SW, et al. Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 2004;25:881-887.
35. Zhang X, Wang Q, Ling MT, et al. Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells. Int J Cancer 2007;120:1891-1898.
36. Wang Y, He QY, Tsao SW, et al. Cytokeratin 8 silencing in human nasopharyngeal cells leads to cisplatin sensitization. Cancer Lett 2008;265:188-196.
37. Mei YP, Zhou JM, Wang Y, et al. Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle 2007;6:1379-1385.